Connect Biopharma Holdings (CNTB) Price & Analysis

Compare

140 Followers

CNTB Stock Chart & Stats

$2.76

$0.04(3.94%)

At close: Jan 08 4:00 PM EST

$2.76

$0.04(3.94%)

Day’s Range― - ―

52-Week Range$0.51 - $3.28

Previous CloseN/A

Volume1.98K

Average Volume (3M)97.97K

Market Cap

$154.29M

Enterprise Value$114.53M

Total Cash (Recent Filing)$71.77M

Total Debt (Recent Filing)$870.00K

Price to Earnings (P/E)―

Beta0.03

Next Earnings

Mar 26, 2026

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding55,903,515

10 Day Avg. Volume111,495

30 Day Avg. Volume97,966

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)0.83

Price to Sales (P/S)2.93

P/FCF Ratio-3.13

Enterprise Value/Market Cap0.74

Enterprise Value/Revenue58.43

Enterprise Value/Gross Profit64.47

Enterprise Value/Ebitda-3.17

Forecast

1Y Price Target

$8.67

Price Target Upside214.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-6.98

Revenue Forecast (FY)$52.37M

Bulls Say, Bears Say

Bulls Say

Acute-care Utility And Readmission ReductionA fast-onset antibody profile could reverse acute exacerbations quickly, reducing hospital admissions and readmissions and supporting use in acute care settings where fast improvement is critical.

Improved Bronchodilator ResponsivenessLaboratory studies using human airway cells and lung tissue showed the drug restored responsiveness to standard bronchodilators when a comparator did not, offering a clear biological explanation for rapid lung function gains.

Mechanism Of ActionPreclinical data indicate the drug binds the target receptor at a unique site, increasing receptor internalization and forming a more stable complex that could translate into stronger biological effects than current therapies.

Bears Say

Competition And Regulatory RiskCompetition from other therapies and uncertainty around regulatory approval create material downside risk to market share and pricing assumptions.

Conservative Sales ModelingAnalyst models that focus only on the acute setting may understate upside if the therapy later gains a chronic-use indication or broader commercial adoption.

Development And Financing RiskClinical development setbacks or the need for additional financing could delay commercialization and place downward pressure on the company's valuation.

Connect Biopharma Holdings News

Connect Biopharma highlights new mechanism of action data for rademikibart

Connect Biopharma (CNTB) highlighted new mechanism of action data for rademikibart and outlined its priorities for 2026. Development...

2M ago

CNTB

H.C. Wainwright names two best 2026 ideas in SMID-cap biopharma

H.C. Wainwright named Achieve Life Sciences (ACHV) and Connect Biopharma (CNTB) the firm’s two best ideas for 2026...

3M ago

ACHV

CNTB

Connect Biopharma announces board resignation amid U.S. transition

Connect Biopharma Holdings ( ($CNTB) ) has provided an update. On December 17, 2025, Connect Biopharma Holdings announced...

3M ago

CNTB

Connect Biopharma initiated with a Buy at Lake Street

Lake Street analyst Thomas Flaten initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $9 price...

4M ago

CNTB

Connect Biopharma Reports Significant Loss Amid Development Efforts

Connect Biopharma Holdings Ltd. ( ($CNTB) ) has released its Q3 earnings. Here is a breakdown of the...

4M ago

CNTB

Promising Outlook for Connect Biopharma Holdings Driven by Rademikibart’s Potential and Strategic Partnerships

Analyst Julian Harrison from BTIG maintained a Buy rating on Connect Biopharma Holdings and keeping the price target...

4M ago

CNTB

Buy Rating for Connect Biopharma Holdings: Rademikibart’s Market Differentiation and Safety Advantages

Connect Biopharma Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes...

4M ago

CNTB

Connect Biopharma reports Q3 EPS (31c), consensus (24c)

Reports Q3 revenue $16k vs $1.2M last year. “Throughout 2025, we have worked diligently to position Connect for...

4M ago

CNTB

Promising Outlook for Connect Biopharma Holdings: Rademikibart’s Potential in Asthma and COPD

Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Connect Biopharma Holdings. The associated price...

5M ago

CNTB

Connect Biopharma initiated with a Buy at BTIG

BTIG initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $10 price target The firm believes...

5M ago

CNTB

Buy Rating for Connect Biopharma: Promising Clinical Data and Market Potential for Rademikibart

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings and keeping the price...

6M ago

CNTB

Connect Biopharma presents data on rademikibart at ERS Congress

Connect Biopharma (CNTB) Holdings presented data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha antibody, at...

6M ago

CNTB

Connect Biopharma Executives Increase Share Holdings

Connect Biopharma Holdings ( ($CNTB) ) has issued an announcement. Between September 2024 and September 2025, Barry D....

6M ago

CNTB

Connect Biopharma management to meet virtually with Northland

Virtual Meeting to be held on September 23 at 10 am hosted by Northland. Published first on TheFly...

6M ago

CNTB

CNTB FAQ

What was Connect Biopharma Holdings’s price range in the past 12 months?

Connect Biopharma Holdings lowest stock price was $0.51 and its highest was $3.28 in the past 12 months.

What is Connect Biopharma Holdings’s market cap?

Connect Biopharma Holdings’s market cap is $154.29M.

When is Connect Biopharma Holdings’s upcoming earnings report date?

Connect Biopharma Holdings’s upcoming earnings report date is Mar 26, 2026 which is in 2 days.

How were Connect Biopharma Holdings’s earnings last quarter?

Connect Biopharma Holdings released its earnings results on Nov 12, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.247 by -$0.073.

Is Connect Biopharma Holdings overvalued?

According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Connect Biopharma Holdings pay dividends?

Connect Biopharma Holdings does not currently pay dividends.

What is Connect Biopharma Holdings’s EPS estimate?

Connect Biopharma Holdings’s EPS estimate is -0.3.

How many shares outstanding does Connect Biopharma Holdings have?

Connect Biopharma Holdings has 55,903,515 shares outstanding.

What happened to Connect Biopharma Holdings’s price movement after its last earnings report?

Connect Biopharma Holdings reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.247. Following the earnings report the stock price went up 5.921%.

Which hedge fund is a major shareholder of Connect Biopharma Holdings?

Currently, no hedge funds are holding shares in CNTB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Connect Biopharma Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-15.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Connect Biopharma Holdings

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Connect Biopharma Holdings (CNTB) Earnings & Revenues

Historic Earnings Reports

CNTB Stock 12 Month Forecast

Average Price Target

$8.67

▲(214.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.46,3.04,3.62,4.199999999999999,4.779999999999999,5.359999999999999,5.9399999999999995,6.52,7.1,7.68,8.26,8.84,9.419999999999998,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.46,2.937692307692308,3.4153846153846152,3.893076923076923,4.3707692307692305,4.848461538461539,5.326153846153846,5.803846153846154,6.281538461538462,6.759230769230769,7.236923076923077,7.714615384615384,8.192307692307693,{"y":8.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.46,2.809230769230769,3.1584615384615384,3.5076923076923077,3.856923076923077,4.206153846153846,4.555384615384615,4.904615384615385,5.253846153846154,5.603076923076923,5.952307692307692,6.3015384615384615,6.650769230769231,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >